Modafinil Overdose: Symptoms, Risk Levels, and What to Do

This article is a pending-review draft. It has not yet been confirmed by a qualified clinician and should not be used as a substitute for direct medical advice. If you or someone else has taken more modafinil than prescribed and feels unwell, contact Poison Control (1-800-222-1222 in the United States) or emergency services rather than relying on this page.

Modafinil (brand name Provigil) is a Schedule IV controlled substance in the United States, FDA-approved for excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea, and shift-work disorder. It is sometimes used off-label for cognitive enhancement or fatigue in other conditions; that use is not FDA-approved and is not the subject of this page. Modafinil is chemically distinct from amphetamine-class stimulants, and that distinction matters directly for overdose risk, which is the focus below.

Direct answer

Modafinil overdose is rarely life-threatening when modafinil is the only substance involved. Reported effects are dominated by an exaggerated version of its normal stimulant action: fast heart rate, agitation, insomnia, anxiety, and sometimes tremor or nausea, rather than the sedation or respiratory depression seen in opioid or sedative overdose. There is no specific antidote. The published record, anchored in the FDA-approved prescribing information, does not describe a confirmed human death from modafinil taken alone, though modafinil combined with other drugs has been associated with more serious outcomes. This does not mean any amount is safe to take, and it does not establish a precise toxic dose threshold in humans; that threshold has not been rigorously defined in the available literature.

How much modafinil is too much?

The standard therapeutic dose is 200 mg once daily. The FDA-approved label allows up to 400 mg daily for obstructive sleep apnea and narcolepsy in some regimens. The FDA-approved prescribing information discusses overdose experience and describes supportive management, but this draft does not reproduce exact overdose case figures from the label because those numbers could not be independently verified against the current label text during this review cycle and should be confirmed by the medical reviewer before publication.

What can be stated with more confidence, based on the general pharmacology of modafinil and its mechanism (below), is directional rather than a precise cutoff:

• Doses at or modestly above the approved 400 mg ceiling generally produce an intensified version of known side effects (insomnia, headache, mild anxiety) rather than a distinct toxic syndrome.
• Doses several-fold above the therapeutic range are more reliably associated with sustained tachycardia, agitation, and sometimes hypertension.
• No validated human lethal dose has been established in the literature reviewed for this page.

Any ingestion above the prescribed amount warrants a call to Poison Control (1-800-222-1222) or a treating clinician. A wide margin of safety relative to amphetamines is not the same as a harmless drug, and dose-response data in humans above the therapeutic range are limited.

Recognizing modafinil overdose symptoms

Modafinil overdose produces central nervous system excitation and sympathetic activation rather than sedation. Published poison-center case series and clinical reports converge on a similar symptom cluster: tachycardia, agitation, insomnia, tremor, nausea, and anxiety, with most exposures classified as minor or resulting in no lasting effect. Cases described as having more severe or "major" outcomes have consistently involved co-ingestion of other substances, not modafinil alone. This page cites that pattern qualitatively because the specific percentages attached to it in earlier drafts could not be traced to a verifiable primary source and are flagged here for the medical reviewer to confirm or supply a correct citation before publication.

Practical symptom pattern by rough exposure level (directional, not a validated dosing chart):

• Mildly supratherapeutic (roughly up to double the prescribed dose): insomnia, mild anxiety, headache, palpitations, usually self-limited.
• Moderately supratherapeutic: more pronounced tachycardia, agitation, nausea, possible chest discomfort; blood pressure elevation is possible but typically modest.
• Substantially supratherapeutic: sustained tachycardia, marked agitation, hypertension, and a plausible but uncommon risk of seizures, particularly in people with a seizure history or with co-ingested substances that lower seizure threshold.

No case series reviewed for this page attributes ventricular arrhythmia or QTc prolongation to modafinil alone.

Why modafinil overdose differs from amphetamine overdose

Modafinil and amphetamines both promote wakefulness, but through different mechanisms, and that difference plausibly explains why modafinil overdose looks different in practice. Amphetamines force dopamine and norepinephrine release into the synapse by reversing transporter direction, which produces a steep dose-response curve for cardiovascular toxicity, hyperthermia, and rhabdomyolysis. Modafinil's primary described mechanism is inhibition of dopamine reuptake at the dopamine transporter, a less forceful and more self-limiting way of raising synaptic dopamine. PET imaging research in humans has examined dopamine transporter binding after modafinil doses in the approved range, but the specific occupancy percentages attributed to that work in earlier versions of this article require verification and are not restated here as fixed figures.

This mechanistic difference is consistent with, but does not by itself prove, why modafinil overdose more often looks like sustained agitation and tachycardia rather than the hypertensive crisis, hyperthermia, or rhabdomyolysis pattern seen in severe amphetamine poisoning. Modafinil also affects norepinephrine, histamine, orexin, and other systems in the hypothalamus and elsewhere; these secondary pathways contribute to wakefulness but are not established causes of serotonin syndrome or malignant hyperthermia in modafinil overdose specifically.

A decision framework for modafinil overdose situations

The single most consequential variable in a modafinil overdose scenario is not the exact milligram count. It is whether the exposure is modafinil alone or modafinil plus something else, and whether the person falls into a higher-risk category. Use this as a starting triage frame, not a substitute for a poison-control call or clinical evaluation.

The exceptions matter more than the general rule. A "small" overdose in a person with a seizure disorder or on other CNS-active drugs is not the same clinical situation as the same milligram amount in an otherwise healthy adult who took one extra tablet.

Emergency management: what is standard, what is judgment

There is no specific antidote for modafinil. Management described in toxicology practice is supportive:

• Assessment and monitoring. Airway and breathing are rarely compromised in isolated modafinil overdose. A 12-lead ECG is reasonable to rule out arrhythmia, especially with co-ingestants or pre-existing cardiac disease. Continuous cardiac monitoring for several hours is a common practice pattern, though the exact recommended duration should be confirmed against current toxicology guidance rather than a fixed number stated here as settled fact.
• Decontamination. Activated charcoal may be considered soon after ingestion in a patient with a protected airway; this is a judgment call made by the treating clinician, not a universal requirement. Induced vomiting is not recommended for oral overdoses generally.
• Agitation. Benzodiazepines are the typical first-line treatment for overdose-related agitation and anxiety across many stimulant exposures; physical restraint is avoided where possible because it can worsen agitation-related complications.
• Observation. Modafinil's half-life at therapeutic doses is roughly 12 to 15 hours, and this can lengthen with large overdoses if metabolic pathways become saturated. This means a significant overdose can produce a longer symptomatic course than shorter-acting stimulants, which is a genuine and clinically relevant point of confusion for people expecting quick resolution.
• Disposition. Intentional overdoses require psychiatric evaluation before discharge, independent of medical stability.

Accidental double-dosing: the most common real-world scenario

The situation people actually search for is usually not a deliberate large overdose. It is forgetting whether a morning dose was taken and taking a second 200 mg tablet, landing at 400 mg total, which is within the FDA-approved upper dosing range used for some indications. This is generally not dangerous in a healthy adult without cardiac or seizure risk factors. Expect prolonged wakefulness into the evening and possibly mild palpitations. Avoid additional caffeine or stimulants for the rest of the day. Contact the prescribing clinician for documentation, and reserve emergency evaluation for new or concerning symptoms, pre-existing cardiac arrhythmia, uncontrolled hypertension, or seizure history.

Co-ingestants change the picture more than the dose does

Across the published case reports and poison-center summaries examined for this topic, the clearest and most consistent finding is that serious outcomes attributed to modafinil overdose almost always involved another substance: alcohol, benzodiazepines, SSRIs or SNRIs, or additional stimulants including caffeine. Alcohol combined with modafinil can mask subjective sedation while impairing coordination, raising injury risk. SSRI or SNRI combinations raise a theoretical concern for serotonin excess, though confirmed serotonin syndrome specifically from this combination is uncommon in the literature reviewed. Combining modafinil with other stimulants produces additive sympathomimetic effects, i.e., more severe and more sustained tachycardia and agitation than either drug alone would be expected to cause.

Special populations that change the risk calculus

• Hepatic impairment. Reduced liver function can meaningfully raise modafinil exposure at a given dose because hepatic metabolism is a major clearance pathway. Dose adjustment is part of the FDA-approved labeling for hepatic impairment; the exact adjustment recommendation should be confirmed against the current label by the reviewing clinician rather than restated here as a fixed number.
• Cardiac disease. People with structural heart disease, arrhythmia history, or recent cardiac events are more vulnerable to the tachycardia and possible blood pressure effects of overdose and warrant closer monitoring even at doses tolerated by healthy adults.
• Pediatric exposure. Modafinil is not FDA-approved for use under 17 years old. Any pediatric ingestion, accidental or intentional, warrants poison-center contact and emergency evaluation regardless of the amount.
• Pregnancy. Modafinil carries reproductive safety concerns based on animal data referenced in FDA labeling, and it is generally avoided in pregnancy. An overdose during pregnancy should involve obstetric consultation in addition to toxicology management.

What is established, what is plausible, and what is not established

Established: Modafinil has a materially different overdose profile than amphetamines, dominated by agitation and tachycardia rather than the classic amphetamine toxidrome. There is no specific antidote. Management is supportive. No confirmed human fatality from modafinil taken alone appears in the sources reviewed for this page.

Plausible but not rigorously quantified here: A dose-response relationship exists between the size of the overdose and symptom severity, but a precise, validated toxic-dose threshold in humans was not confirmed from the sources available for this draft. Mechanistic differences from amphetamine (reuptake inhibition versus forced release) plausibly explain the milder overdose pattern, but this is an inference from pharmacology rather than a controlled outcome comparison.

Not established: An exact milligram threshold above which modafinil alone becomes life-threatening. The generalizability of older poison-center statistics to current prescribing and off-label use patterns, including telehealth-prescribed off-label cognitive-enhancement use, which may differ from the population studied in older case series.

Preventing accidental double-dosing

Simple, low-cost measures reduce the most common real-world "overdose" scenario, which is unintentional double-dosing:

• A weekly AM/PM pill organizer removes ambiguity about whether a dose was already taken.
• Confirmation-based medication reminder apps help patients with rotating or shift-work schedules track dosing.
• Secure, child-resistant storage matters because modafinil tablets can be mistaken for other small pills by young children, and pediatric exposures are treated as a higher-risk category regardless of dose.

Discuss an overdose contingency plan, including when to call Poison Control versus when to go to an emergency department, at the time modafinil is first prescribed.